Mesoblast Ltd Received its Third Buy in a Row

March 21, 2018 Healthcare, Top Market News 0 Comments
Mesoblast Ltd Received its Third Buy in a Row

By Austin Angelo


After Cantor Fitzgerald and Maxim Group assigned a Buy rating to Mesoblast Ltd in the last month, the company received another Buy, this time from Oppenheimer. Analyst Mark Breidenbach maintained a Buy rating on Mesoblast Ltd (NASDAQ: MESO) yesterday. The company’s shares closed yesterday at $6.11.

Mark Breidenbach, 5 star ranked analyst.
According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 27.7% and a 52.7% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Global Blood Therapeutics, and Sorrento Therapeutics.
Currently, the analyst consensus on Mesoblast Ltd is Strong Buy and the average price target is $17.67, representing a 189.2% upside.
In a report issued on March 7, Maxim Group also maintained a Buy rating on the stock with a $14 price target.
Based on Mesoblast Ltd’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $13.3 million and quarterly net profit of $13.72 million. In comparison, last year the company earned revenue of $428.5K and had a GAAP net loss of $19.84 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products. Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.